Hypomania, Depression, Euthymia: New Evidence in Parkinson’s Disease

Table 2

DRT data of patients with Parkinson’s disease.

	DRT-patients (n-MF+MF),	n-MF,	MF,	(d.f.)	value
L-dopa mg/die	374.5	311.7	462.5	-3.34(68)	0.001
	(206.45)	(205.77)	(175.4)
DA-LEDDs	146.7	152.9	138.0	0.59(70)	0.56
	(112.22)	(128.74)	(85.23)
Total LEDDs	739.6	592.6	945.4	-3.24(70)	0.002
	(485.53)	(376.33)	(549.38)
I-MAO selegiline	0.6	0.6	0.6	0.03(64)	0.975
	(1.6)	(1.64)	(1.56)
I-MAO rasagiline	0.5	0.6	0.3	2.15(66)	0.036
	(0.42)	(0.43)	(0.39)
I-COMT	109.2	41.9	203.3	-2.56(70)	0.012
	(273.45)	(165.56)	(358.62)
L-dopa years	6.1	4.4	8.6	-4.03(69)	<0.0001
	(4.82)	(3.66)	(5.19)
DA-years	5.2	4.7	5.8	-0.65(32)	0.52
	(4.70)	(3.70)	(5.60)

Data are reported as mean (standard deviation). Legend: DA: dopamine agonists; LEDDs: L-dopa equivalent doses; I-MAO: monoamine oxidase inhibitors; I-COMT: catechol-o-methyl transferase inhibitors. Significant values are in bold.